Author:
Fisher Miles,Petrie Mark C,Ambery Philip D,Donaldson Jill,Ye June,McMurray John J V
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference25 articles.
1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006
2. Addition of incretin therapy to metformin in type 2 diabetes;Scheen;Lancet,2010
3. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled
4. Harmony 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise;Nauck;Diabetologia,2013
5. HARMONY 3: 104-week randomized, double blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitaglitin, and glimepiride in patients with type 2 diabetes taking metformin;Ahren;Diabetes Care,2014
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献